No Data
No Data
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $36
LifeSci Capital analyst Cory Jubinville, PhD maintains $Larimar Therapeutics(LRMR.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success
Buy Rating for Larimar Therapeutics Backed by Promising Gene Therapy Advances for Friedreich's Ataxia
Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx Therapeutics, Biogen, Lexeo Therapeutics, Larimar Therapeutics
New York, USA, July 16, 2024 (GLOBE NEWSWIRE) -- Friedreich's Ataxia Market to Grow at a Substantial Growth Rate by 2034, Examines DelveInsight | Key Companies - Retrotope, PTC Therapeutics, Minoryx
Lexeo Stock Drops 24% Amid Friedreich Ataxia Study Results
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Helen of Troy Limited (NASDAQ:HELE) fell sharply during Tuesday's session after the company reported soft first-quarter earnings and lowered its FY25 guidance.Helen of Troy reported
Nvidia, Micron Leading Chip Stocks Higher Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.Shares of NVIDIA Corporation (NASDAQ:NVDA) rose during Tuesday's session.Keybanc analyst John Vinh maintained
No Data